NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: Stock

Company 2024/08/30 17:31:58

U NOVARTIS

Price **102.12**

CHF

Difference 0.20%(0.20)

105.00 95.00 90.00 85.00 10.2023 12.2023 02.2024 04.2024 06.2024 08.2024

Contact Details

NOVARTIS AG Tel: +41-61-324-11-11

- - Fax: +

Lichtstrasse 35 Web: http://www.novartis.com

4056 Basel <u>E-mail: -</u>

Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20:	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity	
Current assets	25,654,333,000		34,149,132,000		41,655,955,000		
Common stock capital		694,361,000		823,428,000		820,946,000	
Fixed assets	61,729,135,000		78,507,846,000		82,154,750,000		
Equity capital of a company		39,347,137,000		54,978,159,000		61,796,015,000	
Cash and cash equivalents	11,272,218,000		6,954,728,000		11,304,638,000		
Accrued liabilities		2,802,694,000		3,079,065,000		4,279,671,000	
Other assets	-		-		-		
Current liabilities		22,211,143,000		26,512,531,000		27,524,019,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		25,825,188,000		31,166,287,000		34,490,672,000	
Different income		-		-		-	
Other liabilities		1,004,088,000		1,459,965,000		1,343,946,000	
Total assets	87,383,469,000	87,383,469,000	112,656,978,000	112,656,978,000	123,810,706,000	123,810,706,000	

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	76,057	101,703	104,323
Equity ratio	45.11%	48.87%	50.03%
Debt-equity ratio	121.69%	104.63%	99.86%

Others

	2023	2022	2021
Tax Expense Rate	6.03%	16.90%	19.62%

NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	40,834,735,000	48,273,766,000	47,199,917,000
Net income	7,699,648,000	6,642,477,000	21,961,593,000
EBIT	8,907,828,867	9,115,981,354	11,236,282,240
Operating income before taxes	8,210,082,000	8,003,445,000	9,872,248,000
Cash Flow	12,992,707,000	13,596,306,000	13,778,909,000
Net interest income	-223,764,000	-627,477,000	-766,155,000
Research and development expenses	7,389,613,000	8,484,798,000	8,722,101,000
Income taxes	495,157,000	1,352,372,000	1,937,330,000
Result from investments in subsidaries, associates and other	-11,682,000	-8,595,000	14,023,932,000
Revenues per employee	567,070	501,330	477,867

s
Member of the administrative board
Chairman of the administrative boar

Members of Management Board		
Vasant (Vas) Narasimhan	Chairman of Managing Board	
Klaus Moosmayer	Member of Executive Committee	
Steffen Lang	Member of Executive Committee	
Aharon Gal	Member of Executive Committee	
Fiona H. Marshall	Member of Executive Committee	
Harry Kirsch	Member of Executive Committee	
Karen Hale	Member of Executive Committee	
Kees Roks	Member of Executive Committee	
Lutz Hegemann	Member of Executive Committee	
Michelle Weese	Member of Executive Committee	
Patrick Horber	Member of Executive Committee	
Rob Kowalski	Member of Executive Committee	
Shreeram Aradhye	Member of Executive Committee	
Victor Bulto	Member of Executive Committee	